Biocryst Pharmaceuticals (BCRX)VA awarded $30K

$30K

committed so far

Signed

May 21, 2026

Updated

May 21, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 6, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
2. May 19, 2026Federal contract · $151K obligatedDepartment of Veterans Affairs awarded BIOCRYST PHARMACEUTICALS INC: $151K obligated to date
3. May 21, 2026 · this disclosureFederal contract · $30K obligatedDepartment of Veterans Affairs awarded BIOCRYST PHARMACEUTICALS INC: $30K obligated to date

What came next

1. Jun 11, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 11, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Company’s stockholders approved, by the affirmative vote of a majority of the shares of the Company’s common stock represented in person or by proxy at the Annual Meeting and voting on the proposal, a proposal to amend and restate the BioCryst…”
2. Jun 25, 2026Company filing · Form 8-K · Restructuring, Reg FDAnnounced job cuts, closures or a restructuring, and shared information with investors“On June 25, 2026, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) approved a plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”).”
3. Jun 25, 2026Company filing · Form 8-K · RestructuringAnnounced job cuts, closures or a restructuring“On June 29, 2026, the Company announced its plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”) as part of the Company’s ongoing strategic evolution to strengthen its rare disease pipeline.”
4. Jul 10, 2026CongressDisclosed purchase of BCRX — reported range $1,001 - $15,000
5. Aug 5, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

How to read USAspending.gov award record

The obligated amount is money the government has legally committed to pay and has set aside in its accounts. The ceiling, which USAspending calls the potential value, is the most the contract could be worth if every option is exercised and every possible order is placed. The ceiling is a limit, not a payment, and it is often many times the obligated amount.

Full guide: Contract ceiling vs obligated amount: the difference

What else is on file for Biocryst Pharmaceuticals

For Biocryst Pharmaceuticals, OQRO holds 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BCRX page.

How this filing works

• Contract ceiling vs obligated amount

Other disclosures at Biocryst Pharmaceuticals

• House Clerk periodic transaction reportSep 4, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 29, 2026
• USAspending.gov award recordMay 19, 2026

Everything OQRO holds on this company is on its BCRX page.